Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | USP7 | Q93009 | 4/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194550 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL1970240 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL14403275 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL3193282 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL1751263 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2239870 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL953506 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL953505 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2244835 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2240156 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| EP-2142505-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008120093-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | AHR, AR, CYP8B1 | RORC 38/4885TACR1 1574/4885GPR119 1782/4885 |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | RORC 2651/4885TACR1 1028/4885GPR119 2066/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | RORC 45/4885TACR1 1302/4885GPR119 1534/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | RORC 45/4885TACR1 1302/4885GPR119 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.